Long acting insulin - Gan & Lee Pharmaceuticals
Alternative Names: GZR-4; Long acting insulin analog - Gan & Lee PharmaceuticalsLatest Information Update: 30 Sep 2025
At a glance
- Originator Gan&Lee Pharmaceuticals
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Type 2 diabetes mellitus
Most Recent Events
- 25 Sep 2025 Gan&Lee Pharmaceuticals plans a phase I safety and pharmacokinetics study in healthy subjects in China (SC, injection) (NCT07193147)
- 10 Sep 2025 Gan & Lee Pharmaceuticals plans a phase IIIb trial for Type 2 diabetes mellitus (T2DM) (Treatment-experienced) in China (SC) (NCT07165223)
- 21 Jun 2025 Efficacy and adverse events data from a phase II trial in Type 2 diabetes mellitus released by Gan&Lee Pharmaceuticals